NuVasive brings porous titanium spine implants to its TLIF offerings


With the launch of its latest spine implant, NuVasive has expanded its porous titanium portfolio to all transforaminal lumbar interbody fusion surgeries, or TLIF procedures.

The new Modulus TLIF-A implant features a design specific for anterior implant positioning and anterior column support. It joins the TLIF-O interbody device line the company launched in June, which feature a lordosis cut in the oblique plane, which makes it easier to align the spine without introducing deformities that affect side-to-side movements.

Both are designed to be inserted and rotated using the same instrument, using the company’s MAS TLIF and MAS Midline access systems, and feature a 3D-printed titanium lattice. That structure mimics the stiffness of bone while providing radiolucency and better visualization compared to solid titanium implants. 


Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

RELATED: NuVasive launches all-in-one spine surgery suite

Meanwhile, the gaps in the implants’ porous endplates allow for new bone in-growth and on-growth, helping to secure it in place between the vertebrae. These additions increase the company’s footprint among interbody fusion devices, part of what it estimates as a $1.2 billion market.

“NuVasive’s implants are designed to combine the inherent benefits of porosity with the advantageous material properties of PEEK and titanium to create implants intelligently designed for fusion, which we believe outperforms traditional and competitive implants in the market,” President Matt Link said in a statement. 

With the Modulus TLIF-A implant, NuVasive plans to launch its full Advanced Materials Science TLIF portfolio in the global market later this year.

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

J&J and Ethicon reached a deal with the attorneys general of 41 states and DC, agreeing to pay nearly $117 million.